Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021

Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021

<b>Background:</b> Palbociclib, when combined with endocrine therapy, represents a valuable treatment option for patients diagnosed with hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer (BC) or metastatic breast cancer (MBC)....

Full description

Saved in:
Bibliographic Details
Main Authors: Cristina Marinela Oprean, Larisa Maria Badau, Ramona Petrita, Mircea Dragos Median, Alis Dema
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Diagnostics
Subjects:
breast cancer
cyclin-dependent kinase 4/6 inhibitor
palbociclib
real-world
Her2 low
Ki67
Online Access:https://www.mdpi.com/2075-4418/15/9/1173
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2075-4418/15/9/1173

Similar Items